MDXG Stock Overview
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.
MiMedx Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.83|
|52 Week High||US$15.99|
|52 Week Low||US$3.04|
|1 Month Change||0%|
|3 Month Change||-17.99%|
|1 Year Change||-65.99%|
|3 Year Change||-5.43%|
|5 Year Change||-74.41%|
|Change since IPO||-24.90%|
Recent News & Updates
|MDXG||US Biotechs||US Market|
Return vs Industry: MDXG underperformed the US Biotechs industry which returned -24.3% over the past year.
Return vs Market: MDXG underperformed the US Market which returned -18.4% over the past year.
|MDXG Average Weekly Movement||11.0%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.6%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: MDXG is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: MDXG's weekly volatility (11%) has been stable over the past year.
About the Company
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins. The company’s patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization.
MiMedx Group Fundamentals Summary
|MDXG fundamental statistics|
Is MDXG overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MDXG income statement (TTM)|
|Cost of Revenue||US$43.58m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.17|
|Net Profit Margin||-7.24%|
How did MDXG perform over the long term?See historical performance and comparison
Is MDXG undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MDXG?
Other financial metrics that can be useful for relative valuation.
|What is MDXG's n/a Ratio?|
Price to Sales Ratio vs Peers
How does MDXG's PS Ratio compare to its peers?
|MDXG PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
TNGX Tango Therapeutics
PRE Prenetics Global
HRTX Heron Therapeutics
MDXG MiMedx Group
Price-To-Sales vs Peers: MDXG is good value based on its Price-To-Sales Ratio (1.7x) compared to the peer average (19.9x).
Price to Earnings Ratio vs Industry
How does MDXG's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: MDXG is good value based on its Price-To-Sales Ratio (1.7x) compared to the US Biotechs industry average (14.1x)
Price to Sales Ratio vs Fair Ratio
What is MDXG's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||1.7x|
|Fair PS Ratio||7.4x|
Price-To-Sales vs Fair Ratio: MDXG is good value based on its Price-To-Sales Ratio (1.7x) compared to the estimated Fair Price-To-Sales Ratio (7.4x).
Share Price vs Fair Value
What is the Fair Price of MDXG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate MDXG's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate MDXG's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MDXG's PEG Ratio to determine if it is good value.
Discover undervalued companies
- Take a look at MiMedx Group's forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.
How is MiMedx Group forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MDXG is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: MDXG is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MDXG is expected to become profitable in the next 3 years.
Revenue vs Market: MDXG's revenue (13.4% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: MDXG's revenue (13.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MDXG's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has MiMedx Group performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MDXG is currently unprofitable.
Growing Profit Margin: MDXG is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MDXG is unprofitable, and losses have increased over the past 5 years at a rate of 48.2% per year.
Accelerating Growth: Unable to compare MDXG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MDXG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: MDXG has a negative Return on Equity (-14.57%), as it is currently unprofitable.
Discover strong past performing companies
How is MiMedx Group's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: MDXG's short term assets ($135.9M) exceed its short term liabilities ($36.6M).
Long Term Liabilities: MDXG's short term assets ($135.9M) exceed its long term liabilities ($52.8M).
Debt to Equity History and Analysis
Debt Level: MDXG has more cash than its total debt.
Reducing Debt: MDXG's debt to equity ratio has increased from 0% to 56.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MDXG has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: MDXG has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 40.8% each year
Discover healthy companies
What is MiMedx Group current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MDXG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MDXG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MDXG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MDXG's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MDXG has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tim Wright (63 yo)
Mr. Timothy R. Wright, also known as Tim, MBA, has been a Director of MiMedx Group, Inc. since June 17, 2019. He has been the Chief Executive Officer at MiMedx Group, Inc. since joining on May 13, 2019. Mr...
CEO Compensation Analysis
Compensation vs Market: Tim's total compensation ($USD4.82M) is above average for companies of similar size in the US market ($USD2.83M).
Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.
Experienced Management: MDXG's management team is considered experienced (2.3 years average tenure).
Experienced Board: MDXG's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MDXG insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.5%.
MiMedx Group, Inc.'s employee growth, exchange listings and data sources
- Name: MiMedx Group, Inc.
- Ticker: MDXG
- Exchange: NasdaqCM
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$430.845m
- Shares outstanding: 112.49m
- Website: https://www.mimedx.com
Number of Employees
- MiMedx Group, Inc.
- 1775 West Oak Commons Court, NE
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.